Haemonetics Expects FY24 Revenue Growth Of 6%-9% Compared To 4%-7% Prior Guidance; Sees Adjusted EPS of $3.60-$3.90 Vs. Prior Guidance Of $3.45-$3.75 And Consensus Of $3.59
Portfolio Pulse from Benzinga Newsdesk
Haemonetics has updated its FY24 revenue growth forecast to 6%-9%, up from the previous 4%-7%. The company also expects its adjusted EPS to be between $3.60 and $3.90, higher than the previous guidance of $3.45-$3.75 and the consensus estimate of $3.59.
August 08, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics has raised its FY24 revenue and EPS forecasts, which could positively impact its stock price in the short term.
Haemonetics has raised its FY24 revenue growth forecast and adjusted EPS, both of which are key indicators of a company's financial health. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100